exceptional service across specialties

The journey for patients with complex, hard-to-diagnose diseases can be long and challenging. Many spend years moving from one specialist to another before receiving a diagnosis, and managing treatment and related difficulties can be a daily struggle.

As a specialty pharmacy focused on supporting patients with these complex conditions, we are committed to guiding you through every stage of theat journey, both clinically and administratively to help you achieve the best possible outcomes. Out Therapy Care Teams are extensively trained in each condition we support, allowing us to tailor our approach to meet the unique needs of every patient. Learn more about the conditions and therapies we support below.

Asthma & Allergy

Asthma is a long term condition causing inflammation to the airways and making it difficult to breathe.

Bleeding Disorders

There are several bleeding disorders such as Hemophilia, Von Willebrand disease, and several clotting factors deficiencies.

Hepatitis B

Chronic Hepatitis B is a virus transmitted by bodily fluids that can lead to serious liver damage.

Hepatitis C

Hepatitis C is an infection caused by a bloodborne virus affecting the liver.

HIV

HIV is a serious viral infection that attacks the body’s immune system and if left untreated can seriously impair the body’s ability to fight off infections.

Inflammatory Bowel Disease

IBD is inflammation of the GI tract manifesting in either Crohn’s disease or Ulcerative colitis.

Multiple Sclerosis

MS is a very complex disease affecting the central nervous system.

Oncology

Oncology involves several different types of cancer and can affect multiple areas of the body.

Pulmonary Hypertension

PH is a rare condition in which high blood pressure occurs specifically in the lungs.

Rheumatology

Many rheumatologic diseases are autimmune conditions often times affecting the joints.

Sickle Cell Disease

Sickle cell disease is caused by a hereditary condition affecting the red blood cells.

Transplant

Transplant refers to the life-saving organ transplantation of a healthy organ to another individual.

Search by Drug

Search by Condition or Specialty

  • Motegrity

    • Drug: Motegrity (prucalopride)
    • Manufacturer: Takeda

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of chronic idiopathic constipation in adults
    • Disease: chronic idiopathic constipation (CIC)
    • Therapeutic Area: Gastroenterology
    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: motegrity.com

  • Movantik

    • Drug: Movantik (naloxegol)
    • Manufacturer: Valinor Pharma | AstraZeneca

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation

    • Disease: opioid-induced constipation (OIC)

    • Therapeutic Area: Gastroenterology

    • Enrollment Form Link: N/A

    • Phone Number: N/A

    • Fax Number: N/A

    • Product Website: movantik.com

  • Myfortic

    • Drug: Myfortic (mycophenolic acid)
    • Manufacturer: Novartis

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant, in combination with other immunosuppressants

    • Disease: solid organ transplant

    • Therapeutic Area: Solid Organ Transplant
    • Enrollment Form Link: www.mycophenolaterems.com

    • Phone Number: N/A

    • Fax Number: N/A
    • Product Website: N/A

  • Nivestym

    • Drug: Nivestym (filgrastim-aafi)
    • Manufacturer: Pfizer

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
        • to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
        • to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
        • to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
        • to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

    • Disease: neutropenia associated with myelosuppressive anti-cancer therapy, hematopoietic stem cell transplantation, cyclic/congenital/idiopathic neutropenia

    • Therapeutic Area: Hematology, Oncology

    • Enrollment Form Link: Financial Assistance
    • Phone Number: 1-877-744-5675
    • Fax Number: N/A
    • Product Website: nivestym.com

  • Nyvepria

    • Drug: Nyvepria (pegfilgrastim-apgf)
    • Manufacturer: Pfizer
    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication: to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

    • Disease: neutropenia associated with myelosuppressive anti-cancer therapy

    • Therapeutic Area: Hematology, Oncology
    • Enrollment Form Link: Pfizer Oncology together
    • Phone Number: 1-877-744-5675

    • Fax Number: N/A

    • Product Website: nyvepria.com

  • Ofev

    • Drug: Ofev (nintedanib)
    • Manufacturer: Boehringer Ingelheim

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication:

      • treatment of idiopathic pulmonary fibrosis in adults
      • treatment of chronic fibrosis interstitial lung diseases with a progressive phenotype in adults
      • slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease in adults
    • Disease: idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD)

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: Prescription Form

    • Phone Number: 855-297-5906 (BI Cares)

    • Fax Number: N/A

    • Product Website: ofev.com

  • Omvoh

    • Drug: Omvoh (mirikizumab-mrkz)
    • Manufacturer: Lilly
    • Route of Administration: Intravenous, Subcutaneous
    • Site of Care: Outpatient
    • Approved Indication:

      • treatment of moderately to severely active Crohn’s disease in adults
      • treatment of moderately to severely active ulcerative colitis in adults
    • Disease: Crohn’s disease, ulcerative colitis
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
    • Enrollment Form Link: omvoh.lilly.com/resources
    • Phone Number: 1-800-LillyRx (1-800-545-5979)
    • Fax Number: 1-844-466-0006
    • Product Website: omvoh.com

  • Opsumit

    • Drug: Opsumit (macitentan)
    • Manufacturer: Johnson & Johnson

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of pulmonary arterial hypertension (PAH, WHO group 1) in adults to reduce the risks of disease progression and hospitalization

    • Disease: pulmonary arterial hypertension

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: referral form
    • Phone Number: 866-228-3546
    • Fax Number: 866-279-0669
    • Product Website: opsumit.com

  • Opsynvi

    • Drug: Opsynvi (macitentan/tadalafil)

    • Manufacturer: Johnson & Johnson

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II-III

    • Disease: pulmonary arterial hypertension

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: referral form
    • Phone Number: 866-228-3546

    • Fax Number: 866-279-0669

    • Product Website: opsynvi.com

  • Orenitram

    • Drug: Orenitram (treprostinil)
    • Manufacturer: United Therapeutics

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of pulmonary arterial hypertension (PAH, WHO group 1) to delay disease progression and to improve exercise capacity

    • Disease: pulmonary arterial hypertension

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: orenitramhcp.com/starting-patients
    • Phone Number: 844-864-8437
    • Fax Number: 1-800-380-5294
    • Product Website: orenitram.com